Recon: UK study finds dexamethasone could improve COVID-19 survival; Supreme Court declines to hear generic price fixing challenge

• US narrows list of promising COVID-19 vaccine candidates to about seven (Reuters)
• Supreme Court deals a series of blows to generic drug companies (STAT) (Reuters) (Law360)
• Supreme Court Passes on Eli Lilly Patent Infringement Win (Bloomberg)
• Trump critical of FDA decision to revoke emergency use of drug he has promoted for COVID-19 (Reuters)
• A YouTube ‘hit job’ about a Catalyst Pharma rival is posted amid its battle with the FDA (STAT)
• Proteus files for bankruptcy, reveals it has held acquisition talks with Otsuka (STAT) (CNBC)
• Trump admin pledges Covid-19 vaccines will be free for ‘vulnerable’ Americans (STAT) (CNBC)
• Royalty Pharma IPO Expanded to Raise Almost $2.2 Billion (Bloomberg) (Financial Times)
• German vaccine developer CureVac plans US listing: report (Reuters)
• Jazz Pharma’s $1B bet pays off with accelerated lung cancer approval (Endpoints) (FDA)
• Eli Lilly Says FDA Approves its New Rapid-Acting Insulin Lyumjev (Reuters) (Press)

• First drug proves able to improve survival from COVID-19 (AP) (STAT) (Politico) (NYTimes) (Reuters)
• Coronavirus Vaccine Makers Are Hunting for Vital Equipment: Glass Vials (WSJ)
• Spain is likely to join European deal to buy COVID-19 vaccine from AstraZeneca (Reuters)
• UK funds human trials of potential COVID-19 vaccine from Imperial (Reuters)
• France gives its drugs industry a shot in the arm to tackle pandemic (Reuters)
• Sanofi to invest 610 millions euros at two French vaccines sites (Reuters)
• Sinopharm touts 100% antibody response for COVID-19 vaccine, already giving to workers (Fierce)
• NICE backs Rozlytrek for subset of NSCLC patients (PharmaTimes)
• Japan Stiffens Foreign Investment Rules for Certain Drug, Medical Device Manufacturers (PharmaJapan)
• Global regulators work towards alignment on policy approaches and regulatory flexibility during COVID-19 (EMA)

• AstraZeneca CEO Soriot says fast-tracked COVID-19 shot will protect for just one year (Fierce)
• China's new virus outbreak needs further testing after 'hypothesis' on cause: WHO (Reuters)
• Coronavirus Breaches Chinese Capital, Rattling Officials (NYTimes)
• EU member states agree specs for coronavirus app interoperability (Reuters)
• All of Us Research Program launches COVID-19 research initiatives (NIH)
• Shares of Martin Shkreli’s Former Company Surge on Limited Coronavirus-Drug Study (WSJ)
• A tech investor’s rude awakening on clinical trials sparks an effort to make them faster for Covid-19 (STAT)
• Coronavirus (COVID-19) Update: Daily Roundup June 15, 2020 (FDA)

• Upcoming market catalysts in Q3 2020 (Nature)
• Gilead sees better days ahead for CAR-T therapy Yescarta with Amsterdam manufacturing hub online (Fierce)
• Magenta's technology attracts another gene therapy developer (BioPharmaDive)
• Takeda spins out a pipeline of ‘interesting but still difficult’ psych drugs in $2B deal as it wraps up a post-merger R&D shakeout (Endpoints)
• Adding billions in value, Eli Lilly succeeds where Pfizer failed, halting breast cancer recurrence (Endpoints)
• A failure at Eli Lilly, the comeback drug teplizumab shows off more upbeat diabetes data in the run-up to an FDA filing (Endpoints)
• Billions on the table, GSK’s Hal Barron antes $120M cash to partner with a specialist in synthetic lethality (Endpoints)
• Eyeing a hot IPO market, 4DMT tops up its cash reserves and preps a leap into the clinic with bespoke gene therapy vectors (Endpoints)
• Mallinckrodt StrataGraft Skin Therapy Could Be The First RMAT-Designated Therapy Approved By US FDA (Pink Sheet)
• US FDA Sees Slow But Steady Progress In Adoption Of Continuous Manufacturing (Pink Sheet)
• MHLW to Propose Two-Third Sampling Rate for Wholesaler Survey for Off-Year Drug Re-Pricing; Go/No-Go Debate to Continue (PharmaJapan)
• 4 Life Sciences Companies Launch IPOs Totaling $588M (Law360)

• FDA Doubles Test Review Staff, Is Prioritizing EUA Reviews For Home-Use And High-Batch Tests (MedtechInsight)
• Heart rhythm bodies see 'clear concerns' with using wearables to detect arrhythmias (MedtechDive)
• Myriad prostate cancer test wins coverage from Aetna (MedtechDive)

• It's not just Charles Lieber: NIH's ongoing investigation has swept up 54 scientists who violated rules about foreign ties (Endpoints)
• Proposed delayed commencement of certain medical device regulatory changes (TGA)